BIO News and Press, Bio-Rad Laboratories Inc. Class A From 08/18/22

Waters Corporation has continued to grow its top line, but some bottom line results have been weak. Fortunately, the picture for the year as a whole continues to look up and the firm's long-term outlook will probably be positive. But shares do not make for an attractive purchase a...

Bio-Rad Laboratories ( NYSE: BIO ) said Wednesday it will acquire Curiosity Diagnostics from Scope Fluidics, a Polish biotechnology firm, for up to $170M. The deal amount consists of ~$100M in cash and up to $70M in future milestone payments. Curiosity Diagnostics...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE New...

Bio-Rad Laboratories, Inc. (BIO) Q2 2022 Earnings Conference Call July 28, 2022 06:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President &a...

Bio-Rad Labs press release ( NYSE: BIO ): Q2 Non-GAAP EPS of $3.38 beats by $0.67 . Revenue of $691.1M (-3.5% Y/Y) beats by $26.5M . For the full-year 2022, the company now anticipates non-GAAP currency-neutral revenue growth to be at the high end of the prior ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent comp...

Diagnostics companies and others that support the life sciences industry are higher in Thursday afternoon trading following Danaher's ( NYSE: DHR ) Q2 2022 top and bottom lines beats . Danaher ( DHR ) is up 8% . Thermo Fisher Scientific ( NYSE: TMO ) an...

Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2022 on Thursday, July 28, 2022, following the close of the market. The company will discuss these resu...

The investment case for Bio-Rad hinges almost entirely on performance of its key equity holding, Sartorius AG. Findings show the deep causal relationship between the pair and how a breakdown of this has contributed to heavy losses in FY22. Technical momentum is weak and investors ...